South Africa

Dr. Reddy's in South Africa


We focus on key therapeutic areas like Central Nervous System (CNS) and Primary Care. Our advantageous position is ensured through the presence of key contributors in our business model. Our Research & Development capability helps us ensure enhanced First To Launch Opportunities through non-infringing products and supports differentiation with products and competitors. Alongside, our in-house API manufacturing capabilities assures cost competitiveness in both private and tender based markets. Our Formulation capabilities and strong business development team ensures high-quality in-house product pipeline, shapes licensing strategy to maximize market share and enrich the product basket.

Our Brief History

Dr. Reddy’s Laboratories Ltd. started its operations in South Africa through Triomed who were holding registration for two of our products. Soon after Triomed was acquired by Aspen, we decided to enter the market directly through a joint venture with Venturepharm in 2004. From 2004-2007, through the three year agreement with Pharmaplan we marketed major products.

In August, 2010, the joint-venture became a 100% wholly-owned subsidiary of Dr. Reddy’s. In line with product portfolio and their key drivers, we have migrated to ‘Rx prescription Generation’ model with greater focus on key therapeutic areas and specialist coverage.

 

Milestones:

2010 Dr. Reddy’s Laboratories Ltd. becomes a wholly owned subsidiary. Ranks among Top-20 generic player at 18th position.
2007 The Joint Venture post the three year agreement decided to recruit its own field force. 1 dossier was filed in FY07 with MCC.
2004 First Commercialization of products by Dr. Reddy’s Laboratories Pty. Major alliance and a three year agreement signed with Pharmaplan for hiring sales force after Triomed was acquired by Aspen. Joint venture with Venturepharm initiated. One dossier was filed for FY05.
2000 Dr. Reddy’s Laboratories Ltd. begins its Generic business operation in South Africa through marketing alliance with Triomed for two of its major products.